Literature DB >> 23953783

[Fluid overload and arterial hypertension in hemodialysis patients].

Walid Arkouche1, Philippe Giaime, Lucile Mercadal.   

Abstract

The water sodium overload is a factor of morbi-mortality and its treatment is one of the markers of adequacy of the hemodialysis treatment. Its first clinical assessment was improved by tools such as echocardiography and ultrasonography of the inferior vena cava, the per-dialytic curve of plasma volume, measuring BNP or proBNP and by impedancemetry. The combination of the evaluation of these parameters and of the clinical situation allows one to assess the extracellular overload, the state of the blood volume and the potential of plasma refilling. The latter is a key factor of the per-dialytic hemodynamic tolerance. It is itself a determining factor in weight can be achieved at the end of the session. Getting the "dry" weight can require modifications of the prescriptions of the hemodialysis sessions, a filling by albumin even a drugs support. Finally, the overload treatment is the central part of the treatment of arterial hypertension, which has to benefit however often from antihypertensive treatment the profit of which is demonstrated.
Copyright © 2013 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Antihypertensive treatment; Arterial hypertension; BNP; Brain natriuretic peptid; Courbe de volume plasmatique; Hemodialysis; Hypertension artérielle; Hémodialyse; Impedancemetry; Impédancemétrie; Plasma volume curve; Surcharge hydrosodée; Traitement antihypertenseur; Water sodium overload

Mesh:

Substances:

Year:  2013        PMID: 23953783     DOI: 10.1016/j.nephro.2013.04.004

Source DB:  PubMed          Journal:  Nephrol Ther        ISSN: 1769-7255            Impact factor:   0.722


  1 in total

1.  Fluid status evaluation by inferior vena cava diameter and bioimpedance spectroscopy in pediatric chronic hemodialysis.

Authors:  Xavier Torterüe; Laurène Dehoux; Marie-Alice Macher; Olivier Niel; Thérésa Kwon; Georges Deschênes; Julien Hogan
Journal:  BMC Nephrol       Date:  2017-12-28       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.